Barcelona, Spain – Researchers at the University of Barcelona have developed and validated a novel compound, FLAV-27, that demonstrates the potential to reverse cognitive impairment in animal models of Alzheimer’s disease. Unlike existing treatments that primarily focus on removing amyloid plaques, this experimental drug targets the underlying epigenetic mechanisms contributing to the disease’s progression, offering a potentially transformative approach to combating Alzheimer’s.
The findings, published in the journal Molecular Therapy, represent a significant step toward a new therapeutic strategy based on epigenetics. Alzheimer’s disease, a devastating neurodegenerative disorder, currently affects millions worldwide, and the search for effective treatments remains a critical area of research. Current therapies, such as lecanemab and donanemab, offer limited benefits, slowing cognitive decline by only 27% to 35% and carrying potential side effects, although addressing only one aspect of the disease pathology – the accumulation of beta-amyloid.
FLAV-27 operates through a fundamentally different mechanism. It is the first inhibitor of its kind to target the G9a enzyme, a key regulator of epigenetic changes in the brain. According to Aina Bellver Sanchis, researcher at the Institute of Neurosciences of the UB (UBneuro) and first author of the study, “The compound FLAV-27 represents an innovative and promising approach to Alzheimer’s, with the potential to modify the disease, as it does not act only on its symptoms or a single pathological biomarker, but directly on its underlying molecular mechanisms.” The G9a enzyme contributes to silencing genes crucial for neuronal development, synaptic plasticity, and memory consolidation.
The study revealed that inhibiting G9a with FLAV-27 not only reduced classic pathological markers like beta-amyloid and phosphorylated tau protein – hallmarks of Alzheimer’s – but also restored cognitive function, social behavior, and synaptic structure in various models. These included in vitro assays, the nematode worm C. Elegans (where it improved mobility, lifespan, and mitochondrial respiration), and both early and late-stage Alzheimer’s mouse models.
Identifying a Biomarker for Disease Progression
Researchers also identified a biomarker that can be measured in both the brain and blood plasma of patients. They found that the epigenetic mark H3K9me2, the protein SMOC1, and the molecule p-tau181 were significantly elevated and correlated with symptoms such as tau protein accumulation, neuroinflammation, and the degree of cognitive impairment. Administering FLAV-27 to animal models normalized these indicators, coinciding with cognitive recovery.
Current Status and Future Development
While these preclinical results are encouraging, FLAV-27 is still in the advanced preclinical phase and requires further testing before human clinical trials can begin. The next steps include comprehensive toxicology studies in at least two animal species, formulation development, and preparation of a regulatory dossier for submission to relevant agencies to obtain authorization for clinical trials – a process expected to seize several years.
The development of FLAV-27 represents a shift in Alzheimer’s research, moving beyond simply addressing the symptoms of the disease to targeting its root causes. This epigenetic approach offers a potential pathway to modifying the disease course and improving outcomes for individuals affected by this devastating condition. The team’s identification of biomarkers also provides a valuable tool for monitoring disease progression and assessing the effectiveness of potential treatments.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this promising new research? Share your comments below, and help spread awareness by sharing this article with your network.
